Pediatric Respiratory Disease Therapeutics Market 2027 By Drug Class, Disease and Geography | The Insight Partners

Pediatric Respiratory Disease Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class (Anti-Inflammatory Drugs, Bronchodilators, Combination Drugs, Corticosteroid, Monoclonal Antibodies, Others); Disease (Asthma, Cystic Fibrosis, Bronchiolitis, Pneumonia, Tuberculosis, Others) and Geography

Report Code: TIPRE00015284 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Respiratory diseases are pathological conditions affecting the organs and tissues involved in the process of gas exchange complicated during breathing. Management of respiratory disease in infants and children is a challenging task for healthcare professionals. Respiratory illnesses that affect the air passages that includes nasal passages, bronchi, trachea, and lungs. Respiratory diseases are a significant contributor in the mortality and morbidity in the pediatrics.

MARKET DYNAMICS

The pediatric respiratory disease therapeutics market is growing due to the rise in prevalence of heart and lungs related disorder in children. However, the lack of skill professional is expected to hamper the growth of the global pediatric respiratory disease therapeutics market.

MARKET SCOPE

The "Pediatric Respiratory Disease Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Pediatric Respiratory Disease Therapeutics market with detailed market segmentation drug class and disease. The Pediatric Respiratory Disease Therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Pediatric Respiratory Disease Therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The pediatric respiratory disease therapeutics market is segmented on the basis of drug class and disease. Based on drug class, the market is segmented as Anti-Inflammatory Drugs, Bronchodilators, Combination Drugs, Corticosteroid, Monoclonal Antibodies and others. Based on the disease the market is sub segmented into Asthma, Cystic Fibrosis, Bronchiolitis, Pneumonia, Tuberculosis and Others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Pediatric Respiratory Disease Therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Pediatric Respiratory Disease Therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Pediatric Respiratory Disease Therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Pediatric Respiratory Disease Therapeutics market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Pediatric Respiratory Disease Therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Pediatric Respiratory Disease Therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for Pediatric Respiratory Disease Therapeutics in the global market. Below mentioned is the list of few companies engaged in the Pediatric Respiratory Disease Therapeutics market.

The report also includes the profiles of key players in Pediatric Respiratory Disease Therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Novartis AG
  •  Bayer AG
  •  GlaxoSmithKline plc
  •  Merck & Co
  •  Boehringer Ingelheim GmbH
  •  Regeneron Pharmaceuticals
  •  AstraZeneca plc
  •  F. Hoffmann-La Roche AG
  •  Genetech Inc
  •  Vertex Pharmaceuticals

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Pediatric Respiratory Disease Therapeutics Market - By Drug Class
1.3.2 Pediatric Respiratory Disease Therapeutics Market - By Disease
1.3.3 Pediatric Respiratory Disease Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. ANTI-INFLAMMATORY DRUGS
7.3.1. Overview
7.3.2. Anti-Inflammatory Drugs Market Forecast and Analysis
7.4. BRONCHODILATORS
7.4.1. Overview
7.4.2. Bronchodilators Market Forecast and Analysis
7.5. COMBINATION DRUGS
7.5.1. Overview
7.5.2. Combination Drugs Market Forecast and Analysis
7.6. CORTICOSTEROID
7.6.1. Overview
7.6.2. Corticosteroid Market Forecast and Analysis
7.7. MONOCLONAL ANTIBODIES
7.7.1. Overview
7.7.2. Monoclonal Antibodies Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE
8.1. OVERVIEW
8.2. DISEASE MARKET FORECASTS AND ANALYSIS
8.3. ASTHMA
8.3.1. Overview
8.3.2. Asthma Market Forecast and Analysis
8.4. CYSTIC FIBROSIS
8.4.1. Overview
8.4.2. Cystic Fibrosis Market Forecast and Analysis
8.5. BRONCHIOLITIS
8.5.1. Overview
8.5.2. Bronchiolitis Market Forecast and Analysis
8.6. PNEUMONIA
8.6.1. Overview
8.6.2. Pneumonia Market Forecast and Analysis
8.7. TUBERCULOSIS
8.7.1. Overview
8.7.2. Tuberculosis Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Pediatric Respiratory Disease Therapeutics Market Overview
9.1.2 North America Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis
9.1.3 North America Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Drug Class
9.1.4 North America Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Disease
9.1.5 North America Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Pediatric Respiratory Disease Therapeutics Market
9.1.5.1.1 United States Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.1.5.1.2 United States Pediatric Respiratory Disease Therapeutics Market by Disease
9.1.5.2 Canada Pediatric Respiratory Disease Therapeutics Market
9.1.5.2.1 Canada Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.1.5.2.2 Canada Pediatric Respiratory Disease Therapeutics Market by Disease
9.1.5.3 Mexico Pediatric Respiratory Disease Therapeutics Market
9.1.5.3.1 Mexico Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.1.5.3.2 Mexico Pediatric Respiratory Disease Therapeutics Market by Disease
9.2. EUROPE
9.2.1 Europe Pediatric Respiratory Disease Therapeutics Market Overview
9.2.2 Europe Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis
9.2.3 Europe Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Disease
9.2.5 Europe Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Pediatric Respiratory Disease Therapeutics Market
9.2.5.1.1 Germany Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.2.5.1.2 Germany Pediatric Respiratory Disease Therapeutics Market by Disease
9.2.5.2 France Pediatric Respiratory Disease Therapeutics Market
9.2.5.2.1 France Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.2.5.2.2 France Pediatric Respiratory Disease Therapeutics Market by Disease
9.2.5.3 Italy Pediatric Respiratory Disease Therapeutics Market
9.2.5.3.1 Italy Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.2.5.3.2 Italy Pediatric Respiratory Disease Therapeutics Market by Disease
9.2.5.4 Spain Pediatric Respiratory Disease Therapeutics Market
9.2.5.4.1 Spain Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.2.5.4.2 Spain Pediatric Respiratory Disease Therapeutics Market by Disease
9.2.5.5 United Kingdom Pediatric Respiratory Disease Therapeutics Market
9.2.5.5.1 United Kingdom Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.2.5.5.2 United Kingdom Pediatric Respiratory Disease Therapeutics Market by Disease
9.2.5.6 Rest of Europe Pediatric Respiratory Disease Therapeutics Market
9.2.5.6.1 Rest of Europe Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.2.5.6.2 Rest of Europe Pediatric Respiratory Disease Therapeutics Market by Disease
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Pediatric Respiratory Disease Therapeutics Market Overview
9.3.2 Asia-Pacific Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Disease
9.3.5 Asia-Pacific Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Pediatric Respiratory Disease Therapeutics Market
9.3.5.1.1 Australia Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.3.5.1.2 Australia Pediatric Respiratory Disease Therapeutics Market by Disease
9.3.5.2 China Pediatric Respiratory Disease Therapeutics Market
9.3.5.2.1 China Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.3.5.2.2 China Pediatric Respiratory Disease Therapeutics Market by Disease
9.3.5.3 India Pediatric Respiratory Disease Therapeutics Market
9.3.5.3.1 India Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.3.5.3.2 India Pediatric Respiratory Disease Therapeutics Market by Disease
9.3.5.4 Japan Pediatric Respiratory Disease Therapeutics Market
9.3.5.4.1 Japan Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.3.5.4.2 Japan Pediatric Respiratory Disease Therapeutics Market by Disease
9.3.5.5 South Korea Pediatric Respiratory Disease Therapeutics Market
9.3.5.5.1 South Korea Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.3.5.5.2 South Korea Pediatric Respiratory Disease Therapeutics Market by Disease
9.3.5.6 Rest of Asia-Pacific Pediatric Respiratory Disease Therapeutics Market
9.3.5.6.1 Rest of Asia-Pacific Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.3.5.6.2 Rest of Asia-Pacific Pediatric Respiratory Disease Therapeutics Market by Disease
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Pediatric Respiratory Disease Therapeutics Market Overview
9.4.2 Middle East and Africa Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Disease
9.4.5 Middle East and Africa Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Pediatric Respiratory Disease Therapeutics Market
9.4.5.1.1 South Africa Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.4.5.1.2 South Africa Pediatric Respiratory Disease Therapeutics Market by Disease
9.4.5.2 Saudi Arabia Pediatric Respiratory Disease Therapeutics Market
9.4.5.2.1 Saudi Arabia Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.4.5.2.2 Saudi Arabia Pediatric Respiratory Disease Therapeutics Market by Disease
9.4.5.3 U.A.E Pediatric Respiratory Disease Therapeutics Market
9.4.5.3.1 U.A.E Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.4.5.3.2 U.A.E Pediatric Respiratory Disease Therapeutics Market by Disease
9.4.5.4 Rest of Middle East and Africa Pediatric Respiratory Disease Therapeutics Market
9.4.5.4.1 Rest of Middle East and Africa Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.4.5.4.2 Rest of Middle East and Africa Pediatric Respiratory Disease Therapeutics Market by Disease
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Pediatric Respiratory Disease Therapeutics Market Overview
9.5.2 South and Central America Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Disease
9.5.5 South and Central America Pediatric Respiratory Disease Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Pediatric Respiratory Disease Therapeutics Market
9.5.5.1.1 Brazil Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.5.5.1.2 Brazil Pediatric Respiratory Disease Therapeutics Market by Disease
9.5.5.2 Argentina Pediatric Respiratory Disease Therapeutics Market
9.5.5.2.1 Argentina Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.5.5.2.2 Argentina Pediatric Respiratory Disease Therapeutics Market by Disease
9.5.5.3 Rest of South and Central America Pediatric Respiratory Disease Therapeutics Market
9.5.5.3.1 Rest of South and Central America Pediatric Respiratory Disease Therapeutics Market by Drug Class
9.5.5.3.2 Rest of South and Central America Pediatric Respiratory Disease Therapeutics Market by Disease
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. PEDIATRIC RESPIRATORY DISEASE THERAPEUTICS MARKET, KEY COMPANY PROFILES
11.1. NOVARTIS AG
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAYER AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. GLAXOSMITHKLINE PLC
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. MERCK AND CO
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BOEHRINGER INGELHEIM GMBH
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. REGENERON PHARMACEUTICALS
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ASTRAZENECA PLC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. F. HOFFMANN-LA ROCHE AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. GENETECH INC
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. VERTEX PHARMACEUTICALS
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Novartis AG
2. Bayer AG
3. GlaxoSmithKline plc
4. Merck and Co
5. Boehringer Ingelheim GmbH
6. Regeneron Pharmaceuticals
7. AstraZeneca plc
8. F. Hoffmann-La Roche AG
9. Genetech Inc
10. Vertex Pharmaceuticals
TIPRE00015284
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking